From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.
复制标题
DOI：
10.5306/wjco.v8.i1.37
复制
发表时间：
2017-02-10
影响因子：
2.8
通讯作者：
Buti S
中科院分区：
文献类型：
--
作者：
Bersanelli M;Buti S
在实体肿瘤治疗中化疗的时代已经被翻译时代克服之后，随着靶向治疗引入的创新，医学肿瘤学目前正随着免疫检查点抑制物(CKI)抗体的到来而展望一个新的“免疫治疗时代”的曙光。PD-1/PD-L1靶向治疗的出现证明了这个轴在几乎所有人类癌症的免疫逃逸中的重要性。新的长江基建显著延长了存活期，并产生了持久的反应，在多种癌症类型中显示出显著的疗效。本文的目的是综述针对PD-1/PD-L1轴的CKI抗体治疗晚期实体瘤的临床有效性的最新文献，并探讨免疫检查点阻断的横向挑战。
After that the era of chemotherapy in the treatment of solid tumors have been overcome by the “translational era”, with the innovation introduced by targeted therapies, medical oncology is currently looking at the dawn of a new “immunotherapy era” with the advent of immune checkpoint inhibitors (CKI) antibodies. The onset of PD-1/PD-L1 targeted therapy has demonstrated the importance of this axis in the immune escape across almost all human cancers. The new CKI allowed to significantly prolong survival and to generate durable response, demonstrating remarkable efficacy in a wide range of cancer types. The aim of this article is to review the most up to date literature about the clinical effectiveness of CKI antibodies targeting PD-1/PD-L1 axis for the treatment of advanced solid tumors and to explore transversal challenges in the immune checkpoint blockade.